159 related articles for article (PubMed ID: 38323765)
61. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
62. Hypercalcemia secondary to gastrointestinal stromal tumors: parathyroid hormone-related protein independent mechanism?
Jasti P; Lakhani VT; Woodworth A; Dahir KM
Endocr Pract; 2013; 19(6):e158-62. PubMed ID: 24013983
[TBL] [Abstract][Full Text] [Related]
63. Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism.
Nussbaum SR; Potts JT
J Bone Miner Res; 1991 Oct; 6 Suppl 2():S43-50; discussion S61. PubMed ID: 1722383
[TBL] [Abstract][Full Text] [Related]
64. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism.
Kuchay MS; Mathew A; Kaur P; Mishra SK
Arch Endocrinol Metab; 2021 Oct; 65(5):669-673. PubMed ID: 34591412
[TBL] [Abstract][Full Text] [Related]
65. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
66. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
67. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
68. [Medical treatment of malignant hypercalcemia].
Eto S; Nakano Y; Okada Y
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
[TBL] [Abstract][Full Text] [Related]
69. Malignancy hypercalcemia: evaluation of parathyroid function and response to treatment.
Mallette LE; Beck P; Vandepol C
Am J Med Sci; 1991 Oct; 302(4):205-10. PubMed ID: 1928231
[TBL] [Abstract][Full Text] [Related]
70. [The significance of early diagnosis of cancer-related hypercalcaemia].
Radványi I; Csikós A; Balogh S
Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
[TBL] [Abstract][Full Text] [Related]
71. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
72. Conventional treatment of hypercalcemia of malignancy.
Davidson TG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
[TBL] [Abstract][Full Text] [Related]
73. Hypercalcemia of malignancy: pathophysiology and implications for treatment.
Theriault RL
Oncology (Williston Park); 1993 Jan; 7(1):47-50; discussion 52-5. PubMed ID: 8420542
[TBL] [Abstract][Full Text] [Related]
74. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
Størling L; Villadsen GE; Krogh K; Vestergaard P
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
[TBL] [Abstract][Full Text] [Related]
75. [Hypercalcemia is the most common manifestation of hyperparathyroidism].
Yuzawa Y; Watanabe Y
Nihon Rinsho; 1995 Apr; 53(4):864-9. PubMed ID: 7752474
[TBL] [Abstract][Full Text] [Related]
76. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
Harsch IA; Konturek PC
Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
[TBL] [Abstract][Full Text] [Related]
77. Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
El-Hajj Fuleihan G; Drake MT
Metabolism; 2023 Jun; 143():155553. PubMed ID: 37028591
[No Abstract] [Full Text] [Related]
78. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
79. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
80. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]